Give Patrick Reed credit for his resiliency. He has refused to cower in the wake of all the clamor surrounding him, and he put himself right there again at the Sentry Tournament of Champions before losing in a playoff to Justin Thomas.
But make no mistake, the noise is not going away.
If Reed could be heckled with a "cheater'' taunt a moment after hitting his putt on the third extra playoff hole at sleepy Kapalua, imagine the commotion in a few months at, say, the U.S. Open in New York.
If a former player, Chris DiMarco, is calling you out on Twitter (the now-deleted "Just say you cheated and got beat!''), you know things are going to be rough.
And if television analyst Paul Azinger makes a point to say while Reed is dealing with a rules issue during the third round at the Tournament of Champions that he'll always have to be careful because "cameras will be on him like a hawk'' ... well, the "cheating'' charge will continue to dog him.
Reed had a shaky Presidents Cup. He went 1-3 and his caddie, Kessler Karain, was not allowed carry the bag in final-day singles after an altercation a day earlier with a fan. And all this came after Reed's Hero World Challenge rules fiasco during the third round in the Bahamas last month when he was penalized 2 shots for improving his line of play in a waste area. Television replays were not kind, and nor has been the reaction to the incident.
Not once, but twice, Reed appeared to swipe sand from behind his ball when he took practice swings in the waste area. Reed maintained in interviews afterward that replays did not show a big space between his club and the ball, and that the video was misleading.
At the very least, it looked bad for Reed. Even his biggest supporters would have to admit that regardless of intent, the appearance was awful. Reed doubling down on it and showing no contrition surely did not help.
Nor did the fact that no rebuke from the PGA Tour -- at least not publicly -- has been forthcoming.
In the aftermath of the rules violation, the tour's rules official who handled the ruling, Slugger White, said Reed was "a gentleman'' in discussing the situation. And on Sunday in Hawaii, PGA Tour commissioner Jay Monahan addressed a question in which he was asked if Reed should have faced further punishment.
"Golf is a game of honor and integrity, and you've heard from Patrick,'' Monahan said in comments reported by Golf Digest. "I've had an opportunity to talk to Patrick at length when he says that [he] did not intentionally improve [his] lie. As you go back to that moment, and the conversation that he had with Slugger, and the fact that a violation was applied and he agreed to it, and they signed his card and moved on. To me that was the end of the matter.''
Of course, Monahan and the PGA Tour want it to end. The integrity of one of the tour's members being questioned is not great for business. Cheating allegations in golf always come with a high price. But as we've seen, this is unlikely to go away anytime soon.
So what is Reed to do?
A public mea culpa would help. Acknowledge that a mistake was made, apologize, and do your best to move on.
So far, Reed has elected to try to steer clear of the issue. He shot a low final round to get into a playoff, had a great chance to win and ultimately fell short -- then did an interview afterward that he could have easily declined -- and is now ranked 11th in the world.
Playing well is great, but it appears that is not going to be enough.
The first tournament of the new year also offered an example of just how tight the fight will be for one of the four spots for Americans in the Olympic golf tournament this summer in Tokyo.
Thomas' victory further solidified his spot among the top Americans along with Brooks Koepka. Patrick Cantlay's fourth-place finish pushed him ahead of Tiger Woods in the world ranking to sixth and to fourth among the Americans. And while runner-up Xander Schauffele remains behind Woods (seventh) in the world ranking at eighth, he has moved ahead of the reigning Masters champion in the Olympic projection.
The projection for the Olympics begins with the 2018 Quicken Loans National tournament and will conclude on June 22, following the U.S. Open. So it doesn't exactly mirror the current ranking -- tournaments prior to the 2018 Quicken Loans still carry weight in the Official World Golf Ranking but will gradually drop off.
In the current projection, Thomas, Koepka, Schauffele and Cantlay hold down the top four spots, with Woods eighth, but just barely behind fifth-place Dustin Johnson. The ranking formula is complicated and will also be impacted by the tournament minimum divisor of 40 -- which Woods will not make. In the current OWGR, Woods is the fifth American.
The Olympic tournament will take 60 players, with two per country but up to four if players are ranked among the top 15. There are currently 10 Americans in the top 15, and with three major championships, the Players Championship and two World Golf Championship events still to be played, the situation can change frequently.
For Woods, it is going to require a high level of play through the U.S. Open. Not necessarily a win, but several top-5s at the very least.
Koepka, the top-ranked player in the world, has not played competitive golf since withdrawing at the CJ Cup in South Korea in October during the second round due to aggravating a knee injury. Koepka had stem cell treatment on the knee following the Tour Championship, and he pronounced himself good to go at the Shriners Hospital for Children tournament in Las Vegas, where he missed the cut.
He was scheduled to play the WGC-HSBC Champions in China and withdrew, then withdrew just weeks before the Presidents Cup. His agent said he will return next week at the Abu Dhabi HSBC Championship, a European Tour event.
How he fares will be interesting to see. The last time Koepka returned from a lengthy injury -- two years ago following a wrist problem that kept him out for nearly four months -- he went on an impressive run that saw him win two major championships, a total he has since increased to four.
It is unclear when Koepka will make his first 2020 start on the PGA Tour. He is also scheduled to play the Saudi International event on the European Tour at the end of the month.
Justin Thomas had the Sentry Tournament of Champions seemingly won. Then, with two bogeys in his final three holes, it seemed lost. And then in a playoff, Reed was poised to win before Thomas ultimately won.
It was a strange victory for Thomas, who would have rued letting that one get away and was still stunned in the aftermath that he didn't lose.
But there was an eight-hole stretch on Sunday where Thomas made six birdies, showing just how much game he has in varying conditions. That he almost let it get away was odd but part of golf.
And how he has won three of his past seven starts.
Thomas, 26, has won 12 times on the PGA Tour and passed his buddy Jordan Spieth in victories. At the end of 2017, Spieth had 11 victories to seven for Thomas, who is now ranked fourth in the world.
"I feel like I'll really be able to take a lot from this once I figure out whatever it might be,'' a stunned Thomas said afterward.
His 12 victories are the most for any player in his 20s on the PGA Tour.
"Personally, it's not an accomplishment getting to 12; it's an accomplishment winning today,'' Thomas said. "But I'll have fun with my family and celebrate and [this] week we try to get to 13.''
Thomas is in the field for the first full-field event of 2020, the Sony Open.
- Stem Cell Therapy Market Research Report by Cell Source, by Type, by Therapeutic Application, by End-User, by Region - Global Forecast to 2026 -... - October 16th, 2021
- Harvard's R&D alliance with Resilience to advance manufacture of complex medicines - Harvard Gazette - October 16th, 2021
- A New Line of Defense in Blood Cancer: Natural Killer Cell Therapy - Curetoday.com - October 16th, 2021
- Dr. Kahl on the Potential Utility of Frontline CAR T-Cell Therapy in MCL - OncLive - October 16th, 2021
- Rheumatoid Arthritis Stem Cell Therapy Market By Type (Allogeneic Mesenchymal Stem Cells, Bone Marrow Transplant, Adipose Tissue Stem Cells) and By... - October 16th, 2021
- Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress - Yahoo Finance - October 16th, 2021
- Taking aim at the brain, Takeda strikes up cell therapy R&D alliance with Immusoft - MedCity News - October 16th, 2021
- Dr. Erba on the Evolution of Treatment in MCL - OncLive - October 16th, 2021
- Newer Agents for DLBCL Show Potential for Earlier Use in the Course of Treatment - Targeted Oncology - October 16th, 2021
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer - Business Wire - October 16th, 2021
- Worldwide Cell Therapy Consumables Industry to 2031 - Featuring Bio-Techne, Irvine Scientific and Sartorius Among Others - PRNewswire - October 16th, 2021
- International ZIM Network: SmartMed - Regenerative Solutions for the Therapies of Tomorrow - Business Wire - October 16th, 2021
- BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization -... - October 16th, 2021
- FTC Follows Through On Prioritizing Investigations Into False Advertising In Healthcare Markets - Media, Telecoms, IT, Entertainment - United States -... - October 16th, 2021
- Molecular Atlas of Small Cell Lung Cancer Reveals Unusual Cell Type That Could Explain Why Its So Aggressive - On Cancer - Memorial Sloan Kettering - October 16th, 2021
- Actress Jennifer Garner Visits with 7-Year-Old Girl Fighting B-cell Acute Lymphoblastic Leukemia; What is the Treatment for This Disease? -... - October 16th, 2021
- Four-year-old girl with stage four cancer trying to get to America for clinical trial - Lancashire Telegraph - October 16th, 2021
- Stem cell & gene therapy to treat osteogenesis imperfecta: hype or hope - Open Access Government - October 5th, 2021
- Chennai-based institute to begin clinical trial on stem cell therapy for liver disease - The New Indian Express - October 5th, 2021
- "Stem cell-based therapeutics poised to become mainstream option - BSA bureau - October 5th, 2021
- Anja Health Disrupts Cord Blood Banking with Heartfelt Founding Story and Ground-Breaking Mission - Digital Journal - October 5th, 2021
- Longeveron Successfully Advancing its Cell-Based Therapy Studies in a Growing Industry Segment - Yahoo Finance - October 5th, 2021
- Ready to Treat Over 80 Life-Threatening Diseases, Discover the Potential of Cord Blood during World Cord Blood Day 2021 - PRNewswire - October 5th, 2021
- Transforming Growth Factor Sales Gaining Traction & to reach US$ 709.9 Mn with Significant Development in Cell Therapy Research - PRNewswire - October 5th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - WITN - October 5th, 2021
- Brazil investigates the use of stem cells in the treatment of covid-19 The Clare People - The Clare People - October 5th, 2021
- Indianapolis mother gives 13-year-old son with sickle cell disease a 2nd chance at life - WTHR - October 5th, 2021
- US FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | DNA RNA and... - October 5th, 2021
- Lack of awareness about blood stem cell donation is one of the leading causes for low number of donors in In.. - ETHealthworld.com - October 5th, 2021
- 'Survivor' winner Ethan Zohn opens up about his cancer battle: I was a healthy, young guy. You never expect it to be you. - Yahoo Life - October 5th, 2021
- The Best Skincare Treatments For Time-Crunched Moms (Or Anyone Else Who Only Has Five Minutes To Spare) - Forbes - October 5th, 2021
- [PDF] Stem Cell Therapy Market Size Strong Revenue and Generated Opportunities UNLV The Rebel Yell - UNLV The Rebel Yell - August 31st, 2021
- Mike Tysons weird stem cell treatment has helped transform incredible body at 55 - Daily Star - August 31st, 2021
- Acute Monocytic Leukemia: Causes, Symptoms, and Treatment - Healthline - August 31st, 2021
- UC Davis and the School of Medicine set new records in research funding - UC Davis Health - August 31st, 2021
- NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer - Cancer Network - August 31st, 2021
- DHEC Supports Awareness and Education during National Sickle Cell Awareness Month - SCDHEC - August 31st, 2021
- The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation - DocWire News - August 31st, 2021
- Global Cryopreservation Equipment Market Report 2021-2028 - Growing Acceptance for Regenerative Medicine & Increasing Needs of Biobanking... - August 31st, 2021
- Operational Highlights and Financial Results for the Year Ended June 30, 2021 - GlobeNewswire - August 31st, 2021
- Event to benefit 2 families with kids fighting cancer - Youngstown Vindicator - August 31st, 2021
- Cryo-Cell International Announces Uplisting to The Nasdaq Capital Market - GlobeNewswire - August 31st, 2021
- Incyte and MorphoSys Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults... - August 31st, 2021
- Thomas Smeenk with an update on the FDA Phase II clinical trial program of the Hemostemix blood-derived, stem cell therapeutics product (ACP-01) -... - August 31st, 2021
- 2021 Pipeline Insight Report on Myocardial Infarction - Featuring AstraZeneca, Mesoblast and Boehringer Ingelheim Among Others -... - August 31st, 2021
- Mini brains grown in the lab sprout primitive eyes - Freethink - August 31st, 2021
- BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA (Dinutuximab Beta) for Patients With High-Risk Neuroblastoma - Business Wire - August 18th, 2021
- Study Calls for COVID-19 Vaccination in Patients With Cancer to Enable Optimal Treatment Delivery During Pandemic - OncLive - August 18th, 2021
- Treatment of AML in Older Patients Almost At 'The Holy Grail' - Curetoday.com - August 18th, 2021
- Animal Stem Cell Therapy Market Identify Key Drivers, Trends, Latest Innovations, Business Senario, Demand With Outlook by 2026 - The Market Writeuo -... - August 18th, 2021
- 8 Tips for Coping With a Diagnosis of PPMS - Everyday Health - August 18th, 2021
- More positive results from CRISPR trial for sickle cell and thalassaemia - BioNews - August 18th, 2021
- Belumosudil Granted Full Approval for Treatment of Chronic GVHD by FDA - Cancer Network - July 22nd, 2021
- Dr. Martin on the Role of Maintenance Therapy With Rituximab in MCL July 15th 2021 Peter - OncLive - July 22nd, 2021
- FDA tells Magenta to pump the brakes on blood cancer trial before it starts to develop new dosing test - FierceBiotech - July 22nd, 2021
- Stemson Therapeutics Secures $15M Series A Funding to Cure Hair Loss - Business Wire - July 22nd, 2021
- Events planned to support 5-year-old's cancer treatments - The Augusta Chronicle - July 22nd, 2021
- HER2-Specific CAR T Cells Induce Early Efficacy Without Dose-Limiting Toxicities in Pediatric CNS Tumors - OncLive - July 22nd, 2021
- A mother's love: Two years after devastating crash, Abby Roby has hope - London Free Press (Blogs) - July 22nd, 2021
- Roswell Park Team Shows Dendritic-Cell Vaccines Can Be Paired With Standard Therapy for Breast Cancer - Newswise - July 22nd, 2021
- Introducing the 3D bioprinted neural tissues with the potential to 'cure' human paralysis - 3D Printing Industry - July 22nd, 2021
- Investing in stem cells, the building blocks of the body - MoneyWeek - June 25th, 2021
- Discrepancies Between Real-World Patterns of Care and Recommendations Based on Clinical Trials Exist in MCL - OncLive - June 25th, 2021
- Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies - PR Web - June 25th, 2021
- Disparities in Utilization of Autologous Stem Cell Transplantation as Consolidative Therapy for Multiple Myeloma: A Single Institution Retrospective... - June 25th, 2021
- Vita Therapeutics Raises $32 Million in Oversubscribed Series A Financing Led by Cambrian Biopharma to Advance the Development of Therapies to Treat... - June 25th, 2021
- Updates in the treatment of peripheral T-cell lymphomas | JEP - Dove Medical Press - June 25th, 2021
- Novel Tafasitamab Combination Finds a Role in Second-line DLBCL Treatment - Targeted Oncology - June 25th, 2021
- Global Nerve Repair and Regeneration Devices Market to Reach $11. 8 Billion by 2026 - GlobeNewswire - June 25th, 2021
- 5 potential benefits of exosome treatment - AZ Big Media - June 8th, 2021
- Orion and the Blood Service launch collaboration to develop new CAR T-cell cancer therapy - Yahoo Finance Australia - June 8th, 2021
- Improvements in the Treatment of Patients With MCL Over the Past Decade - Oncology Learning Network - June 8th, 2021
- Novo Nordisk partners with Heartseed on heart failure cell therapy - PMLiVE - June 8th, 2021
- Citius Pharmaceuticals to be Added to Russell 2000 Index - BioSpace - June 8th, 2021
- IN8bio Completes Treatment of First Cohort in Phase 1 Clinical Trial with Gamma Delta T-Cell Therapy in Patients with Newly Diagnosed Glioblastoma... - June 8th, 2021
- Regenerative medicine: moving next-gen treatments from lab to clinic - Pharmaceutical Technology - June 8th, 2021
- Global $30+ Billion Cell Therapy Bioprocessing Market to 2028: Market Opportunities in Automated Procedures to Produce Cell Therapies - PRNewswire - June 8th, 2021
- Global Stem Cell & Regenerative Medicine Market Report Forecast to 2027 3M Group Novartis AG Integra Gene Therapies The Manomet Current - The... - June 8th, 2021
- Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients with Multiple Myeloma - Curetoday.com - June 8th, 2021
- BioRestorative Therapies to Present at the Emerging Growth Conference on June 9, 2021 - StreetInsider.com - June 8th, 2021